Cantor Fitzgerald Expects StemCells (STEM) to Present GA Data This Week; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
June 18, 2015 8:05 AM EDTNEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor... More
StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
June 18, 2015 8:05 AM EDTNEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor... More
